Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.01, but opened at $15.55. Gyre Therapeutics shares last traded at $13.82, with a volume of 31,659 shares.

Gyre Therapeutics Stock Performance

The business has a 50 day moving average of $13.77 and a 200 day moving average of $13.02.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The company had revenue of $25.23 million for the quarter. Analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GYRE. FMR LLC bought a new position in Gyre Therapeutics during the third quarter worth about $47,000. Rhumbline Advisers bought a new position in Gyre Therapeutics during the second quarter worth about $123,000. Renaissance Technologies LLC bought a new position in Gyre Therapeutics during the second quarter worth about $166,000. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics during the second quarter worth about $218,000. Finally, WINTON GROUP Ltd bought a new position in Gyre Therapeutics during the second quarter worth about $220,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.